共 346 条
[1]
Bennett CL(2013)Colony-stimulating factors for febrile neutropenia during cancer therapy N Engl J Med 368 1131-1139
[2]
Djulbegovic B(2006)Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients Cancer 106 2258-2266
[3]
Norris LB(2012)Pharmacoeconomics of the myeloid growth factors: a critical and systematic review Pharmacoeconomics 30 497-511
[4]
Armitage JO(2011)Costs and outcomes associated with hospitalized cancer patients with neutropenic complications: a retrospective study Exp Ther Med 2 859-866
[5]
Kuderer NM(2003)Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524-4531
[6]
Dale DC(1998)The economics of febrile neutropenia: implications for the use of colony-stimulating factors Eur J Cancer 34 1857-1864
[7]
Crawford J(1996)Use of G-CSF to sustain dose intensity in breast cancer patients receiving adjuvant chemotherapy: a pilot study Cancer Control 3 519-523
[8]
Cosler LE(2005)Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy Cancer 103 1916-1924
[9]
Lyman GH(2007)Economic burden of chemotherapy-related febrile neutropenia J Support Oncol 5 44-55
[10]
Hirsch BR(2008)Cost of neutropenic complications of chemotherapy Ann Oncol 19 454-460